Phosphofructokinase P fine-tunes T regulatory cell metabolism, function, and stability in systemic autoimmunity.
Marc ScherlingerWenliang PanRyo HisadaAfroditi BoulougouraNobuya YoshidaMilena VukelicMasataka UmedaSuzanne KrishfieldMaria G TsokosGeorge C TsokosPublished in: Science advances (2022)
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by defective regulatory T (T reg ) cells. Here, we demonstrate that a T cell-specific deletion of calcium/calmodulin-dependent protein kinase 4 (CaMK4) improves disease in B6. lpr lupus-prone mice and expands T reg cells. Mechanistically, CaMK4 phosphorylates the glycolysis rate-limiting enzyme 6-phosphofructokinase, platelet type (PFKP) and promotes aerobic glycolysis, while its end product fructose-1,6-biphosphate suppresses oxidative metabolism. In T reg cells, a CRISPR-Cas9-enabled Pfkp deletion recapitulated the metabolism of Camk4 -/- T reg cells and improved their function and stability in vitro and in vivo. In SLE CD4 + T cells, PFKP enzymatic activity correlated with SLE disease activity and pharmacologic inhibition of CaMK4-normalized PFKP activity, leading to enhanced T reg cell function. In conclusion, we provide molecular insights in the defective metabolism and function of T reg cells in SLE and identify PFKP as a target to fine-tune T reg cell metabolism and thereby restore their function.
Keyphrases
- systemic lupus erythematosus
- disease activity
- induced apoptosis
- cell cycle arrest
- rheumatoid arthritis
- crispr cas
- protein kinase
- cell death
- ankylosing spondylitis
- endoplasmic reticulum stress
- type diabetes
- hydrogen peroxide
- single cell
- stem cells
- metabolic syndrome
- skeletal muscle
- air pollution
- insulin resistance
- single molecule